

Supplemental Table 1: Baseline characteristics of tesamorelin-treated subjects with ALT or AST > 30 U/L by VAT responder status at week 26

Variable	VAT responders (n = 177)	VAT nonresponders (n = 80)	P-value
<i>Demographic</i>			
Age (y)	47.6 ± 7.0	47.6 ± 7.1	0.94
Male %	94	93	0.58
Race %			0.43
White	85	79	
Black	7	11	
Asian	0	1	
Hispanic	6	8	
Other	2	1	
Hepatitis C %	6	19	0.002
Any viral hepatitis %	21	38	0.009
Testosterone %	27	29	0.76
Lipid-lowering therapy %	53	48	0.42
<i>Immunologic</i>			
CD4 (cells/mm ³)	632 ± 318	624 ± 294	0.85
Undetectable viral load %	76	73	0.34
ART %			0.35
NRTI alone	5	6	
NRTI + NNRTI	39	48	
NRTI + PI	41	29	
NRTI + NNRTI + PI	11	10	
Other	5	8	
<i>Metabolic</i>			
BMI (kg/m ²)	28.7 ± 3.6	29.6 ± 4.6	0.09
VAT (cm ²)	190 ± 83	202 ± 77	0.27
SAT (cm ²)	202 ± 108	221 ± 122	0.23
Fat in limbs (kg)	6.1 ± 3.5	7.2 ± 4.4	0.03
Lean body mass (kg)	64.4 ± 8.7	65.5 ± 10.9	0.37
ALT (U/L)	50 ± 20	53 ± 23	0.31
AST (U/L)	37 ± 13	39 ± 15	0.46
IGF-1 (ng/mL)	151 ± 59	158 ± 68	0.46

Mean ± SD

VAT, visceral adipose tissue; ART, antiretroviral therapy; NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; BMI, body mass index; SAT, subcutaneous adipose tissue; ALT, alanine aminotransferase; AST, aspartate aminotransferase; IGF-1, insulin-like growth factor 1.

Supplemental Table 2: Changes among tesamorelin-treated subjects with baseline ALT or AST > 30 U/L by VAT responder status at week 26

A) Changes in ALT, AST, and VAT

	Baseline			Δ (Week 26 – Week 0)		
	Responder (n = 177)	Nonresponder (n = 80)	<i>P</i> -value	Responder (n = 176)	Nonresponder (n = 79)	<i>P</i> -value
ALT (U/L)	50.0 ± 20.3	52.9 ± 23.2	0.31	-8.9 ± 22.6	1.4 ± 34.7	0.004 ¹
AST (U/L)	37.4 ± 12.9	38.8 ± 15.0	0.46	-3.8 ± 12.9	0.4 ± 22.4	0.04 ¹
VAT (cm ²)	190 ± 83	202 ± 77	0.27	-51 ± 34	16 ± 27	N/A

B) Frequency of resolution of abnormal liver enzymes (ALT or AST ≤ 30 U/L at week 26)

	Responder (n = 176)	Nonresponder (n = 79)	<i>P</i> -value	Odds Ratio (95% CI)
ALT (U/L)	35%	18%	0.007	2.5 (1.2, 5.3) ²
AST (U/L)	52%	41%	0.10	1.5 (0.8, 2.8) ²

Mean ± SD

ALT, alanine aminotransferase; AST, aspartate aminotransferase; VAT, visceral adipose tissue.

¹*P*-value for responder status is based on the following model: Δ ALT or AST = baseline ALT or AST + responder status + clinical trial + viral hepatitis status

²Odds Ratio for responder vs. nonresponder is based on the following model: ALT or AST ≤ 30 U/L = baseline ALT or AST + responder status + clinical trial + viral hepatitis status